B · Normal
[Novo Nordisk announced the latest research results of semaglutide: nearly 80% of obese children aged 6 to 12 years old reduced their BMI by 10% or more] November 17th, Novo Nordisk announced the main results of the STEP Young phase 3 clinical trial on November 16th. The trial was designed to evaluate the safety and efficacy of investigational once-weekly semaglutide injection at a maximum dose of 1.7 mg or 2.4 mg based on baseline body weight in obese children aged 6 to less than 12 years, in addition to caloric restriction and increased physical activity. The results of the study showed that Wegovy (Novogen) reduced the BMI of nearly 80% of obese children aged 6 to 12 years by 10% or more, compared with 0% in the placebo group.
Novo Nordisk 🕐 2026-11-17 20:51

Related telegraphs

Comments

0/500
Captcha (click to refresh)
No comments yet